Information

Information Close

New Citations in February 2026
2026-03-12 300

New Citations in February 2026

In February 2026, AntibodySystem products powered multidisciplinary research worldwide. Molecular Cancer revealed how Fusobacterium nucleatum manipulates host autophagy for immune evasion in nasopharyngeal carcinoma. Advanced Materials presented a circular RNA strategy to prevent vascular graft restenosis. Advanced Science showed indole-3-propionic acid improves bronchopulmonary dysplasia via autophagic flux regulation. Neoplasia uncovered the "energy symbiosis" between bladder cancer cells and adipocytes via fatty acids. Studies on Lassa virus drug repurposing, VDAC1-mtDNA in disc degeneration, and costunolide targeting HSP90 for colitis further advanced antiviral and degenerative disease research. AntibodySystem will continue empowering global researchers to expand the frontiers of life sciences and translational medicine.

IF 33.9 Molecular Cancer

Title: Fusobacterium nucleatum manipulates host autophagy to promote its intracellular survival and treatment resistance in nasopharyngeal carcinoma

Core Finding: This study reveals that Fusobacterium nucleatum (F. nucleatum), particularly its C2 clade (Fna C2), promotes its persistent intracellular survival in nasopharyngeal carcinoma (NPC) cells by secreting the virulence protein FadA. FadA recruits the E3 ubiquitin ligase TRIM28, which in turn facilitates K48-linked ubiquitination and subsequent degradation of the host RAB7A protein. This degradation disrupts autophagic flux by blocking autophagosome–lysosome fusion. The intracellular persistence of the bacterium consequently renders tumor cells resistant to radiotherapy and chemotherapy. Clinical sample analysis further confirms that high intratumoral abundance of F. nucleatum is significantly associated with poor prognosis and tumor recurrence in NPC patients.

Cited Product: Catalog No. YHE80201｜Recombinant Human RAB7A Protein, N-His

Product Application: This product was employed in GST pulldown assays to validate the direct physical interaction between FadA and RAB7A, providing critical experimental evidence for the molecular mechanism by which FadA mediates RAB7A degradation.

IF 26.8 Advanced Materials

Title: Safeguarding VSMC Contractile Phenotype With In Situ circRNA-mediated Endothelial Olaratumab Engineering to Prevent Vascular Graft Stenosis

Key Finding: The study developed a functionalized small-diameter vascular graft (SDVG) utilizing circRNA-lipid nanoparticle (LNP) technology. This platform enables in situ expression of olaratumab (Ola) in vascular endothelial cells (ECs), precisely inhibiting platelet-derived growth factor receptor-alpha (PDGFR-α) signaling. The LNPs, dual-modified with RGD and CD47, achieve targeted EC delivery while minimizing macrophage phagocytosis. The encapsulated circRNA facilitates sustained Ola secretion from ECs, which, by blocking PDGF-BB-mediated MAPK and PI3K-AKT pathways, suppresses the phenotypic switch of vascular smooth muscle cells (VSMCs) to a synthetic state, reducing cell migration, invasion, and excessive extracellular matrix deposition. In vivo studies demonstrated that the graft enabled sustained Ola secretion for up to 24 days, accelerated endothelialization, and significantly reduced neointimal hyperplasia and graft calcification over six months, ultimately improving long-term vascular graft patency.

Cited Product: KDD16101 ｜ Olaratumab ELISA Kit

Application: This kit was used in ELISA assays to quantitatively measure Ola concentrations in cell culture supernatants, intracellular extracts, and animal blood samples. Results confirmed that CM-LNP-mediated Ola secretion exhibited longer duration and greater stability both in vitro and in vivo compared to LM-LNP.

IF 14.1 Advanced Science

Title: Indole-3-Propionic Acid Improves Alveolar Development Impairment via Targeting VAMP8-mediated SNAREs Complex Formation in Bronchopulmonary Dysplasia

Key Finding: This research identifies the tryptophan metabolite indole-3-propionic acid (IPA) as a key metabolite associated with bronchopulmonary dysplasia (BPD). IPA levels were significantly downregulated in both clinical BPD patients and a hyperoxia-induced BPD mouse model. Mechanistically, IPA directly binds to vesicle-associated membrane protein 8 (VAMP8) and inhibits its phosphorylation. This stabilizes the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex (comprising VAMP8, STX17, and SNAP29), promoting autophagosome-lysosome fusion and restoring autophagic flux. Consequently, IPA exerts pro-proliferative, anti-apoptotic, and pro-transdifferentiation effects, ameliorating hyperoxia-induced alveolar development arrest. Animal studies confirmed that IPA intervention restored lung function, reduced alveolar simplification, and mitigated lung tissue damage in a BPD mouse model, suggesting a novel therapeutic target for BPD.

Cited Product: YHK73201 ｜ Recombinant Human VAMP8 Protein, N-His-SUMO & C-Strep

Application: This recombinant protein was utilized for circular dichroism (CD) spectroscopy and surface plasmon resonance (SPR) assays. CD analysis revealed that IPA induces conformational changes in the secondary structure of VAMP8, while SPR confirmed their specific binding (KD = 5.08×10⁻⁶ M), providing crucial evidence for the molecular mechanism of IPA targeting VAMP8.

IF 7.7 Neoplasia

Title: White-to-brown adipose switching promotes bladder cancer progression

Key Finding: Bladder cancer cells secrete PTHrP, which induces browning of perivesical adipose tissue via the PKA signaling pathway. The released free fatty acids (FFAs) are subsequently taken up by cancer cells, reprogramming lipid metabolism and promoting bladder cancer proliferation, invasion, and metastasis. Pharmacological inhibition of PKA with H89 reversed this process. Clinically, high PTHrP/UCP1 expression correlates with poor prognosis in bladder cancer patients, identifying this signaling axis as a potential therapeutic target.

Cited Product: RHC93101 ｜ Anti-Human PTHrP/PTHLH (1-34) Antibody (SAA0326)

Application: This antibody was employed as a PTHrP neutralizing antibody in cell co-culture systems, adipocyte treatment experiments, and animal studies. Its use helped validate the critical role of PTHrP in adipose tissue browning, FFA release, and bladder cancer malignant progression, providing core experimental evidence for elucidating the underlying molecular mechanisms.

IF 6.1 Talanta

Title: Structural tuning of bridging linkers on M13 phages for high-affinity detection of enterovirus A71

Key Finding: This study screened and identified EV-A71 VP1-specific M13 phage ligands. By optimizing the bridging linker with PEG4-biotin chemical modification, a colorimetric biosensor was constructed. The sensor exhibited excellent linear responses to both VP1 (0.03-3.91 nM) and intact EV-A71 viral particles (10²-10⁶ PFU/mL), achieving detection limits of 0.22 nM and ~10² PFU/mL, respectively. It maintained high sensitivity and specificity even in complex matrices like serum and sewage, offering a promising new platform for rapid on-site detection of EV-A71.

Cited Product: YVV20301 ｜ Recombinant EV71 VP1/Capsid protein VP1 Protein, N-His

Application: This recombinant protein served as the target for phage display technology to screen and identify high-affinity EV-A71 VP1-specific M13 phage ligands, establishing the essential target foundation for constructing the phage-based colorimetric biosensor.

IF 4.7 International Immunopharmacology

Title: Covalently targeting HSP90 with a natural small-molecule costunolide to inhibit necroptosis and ulcerative colitis

Key Finding: This study reveals that costunolide (CTL), a natural compound, acts as a novel necroptosis inhibitor. CTL covalently binds to Cys572 of HSP90AA1 and Cys564 of HSP90AB1, allosterically inhibiting HSP90 dimerization and its chaperone function. This disrupts the interaction between HSP90 and RIPK1, blocking the RIPK1/3-MLKL necroptosis signaling axis. In an ulcerative colitis (UC) model, CTL treatment alleviated intestinal damage, reduced necroinflammation, and preserved the mucosal barrier. Cys572/564 are identified as novel druggable sites for allosteric inhibition of HSP90.

Cited Product: YHC31801 ｜ Recombinant Human HSP90AB1 Protein, N-His

Application: This recombinant protein was used for liquid chromatography-mass spectrometry (LC-MS) analysis. HSP90AB1 protein was incubated with CTL, followed by tryptic digestion and mass spectrometry, which identified covalent modification of the Cys564 residue on HSP90AB1 by CTL. This provided crucial experimental evidence for the molecular mechanism by which CTL targets HSP90 to inhibit necroptosis.

IF 4.0 Antiviral Research

Title: Identification of Gemcitabine as an Anti-Lassa Virus Inhibitor Using a Robust Biosafety Level-2 System Modeling the Complete Virus Life Cycle

Key Finding: Using a newly established BSL-2 LASVsg system, this study screened and identified the clinically approved drug gemcitabine (GEM) as a potent inhibitor of Lassa virus (IC50 = 0.21 μM, SI > 1429). Its antiviral activity was subsequently validated with live virus in a BSL-4 facility. Mechanistic studies revealed that GEM selectively inhibits viral protein translation through a CTP-dependent mechanism, without affecting viral RNA replication or transcription.

Cited Product: RVV04306 | Anti-LASV GPC Antibody (12.1F)

Application: This antibody was utilized in immunofluorescence assays to detect viral GP protein expression, providing key evidence supporting the mechanism by which GEM inhibits viral protein translation.

IF 3.9 Fish & Shellfish Immunology

Title: Dietary 5-aminolevulinic acid induces strain-specific effects on shell color and innate immunity in Pacific oyster (Crassostrea gigas) through divergent porphyrin metabolism

Key Finding: Dietary supplementation with 5-ALA had divergent effects on two oyster strains: it enhanced shell color in orange-shell oysters via PPIX deposition, while boosting immunity in gold-shell oysters via heme synthesis. In gold-shell oysters, heme-mediated activation of the Nrf2 antioxidant pathway and the TLR4-MyD88 immune signaling axis was observed. An optimized dose of 20 mg/L achieved strain-specific trait enhancement without affecting growth.

Cited Product: FHJ82310 | Anti-Human CD338/ABCG2 Antibody (5D3)

Application: This antibody was used in Western blot and immunofluorescence assays to detect differential expression of the CgABCG2 protein in the mantle tissues of the two oyster strains, revealing strain-specific regulatory mechanisms underlying PPIX transport.

IF 3.7 Cellular Signalling

Title: VDAC1-mediated cytosolic leakage of mtDNA triggers pyroptosis of nucleus pulposus cells by activating the TLR9 signaling pathway

Key Finding: This research demonstrates that oxidative stress upregulates VDAC1 expression and promotes its oligomerization. This facilitates the leakage of mitochondrial DNA (mtDNA) into the cytoplasm through VDAC1 pores, subsequently activating the TLR9 signaling pathway. This cascade triggers pyroptosis in nucleus pulposus cells, exacerbating intervertebral disc degeneration (IVDD). Inhibiting VDAC1 or TLR9 effectively blocked this pathway, alleviating cell pyroptosis and slowing IVDD progression, thereby identifying novel therapeutic targets for IVDD.

Cited Product: RGK24020 | Anti-dsDNA Antibody (3E10#)

Application: This antibody was employed in immunofluorescence staining to detect cytosolic mtDNA (dsDNA) leakage, visually demonstrating the effect of the VDAC1 inhibitor NSC15364 in reducing mtDNA release into the cytoplasm.

bioRxiv

Title: A novel antiviral strategy targeting human metapneumovirus through pH modulation in human airway epithelial cells

Key Finding: PHOH-001, an inhaled alkaline buffer, significantly inhibits human metapneumovirus (hMPV) infection by increasing both extracellular and intracellular pH in human airway epithelial cells. Its mechanism involves altering viral F protein localization, disrupting actin organization, and reducing syncytia formation and viral replication. PHOH-001 demonstrated efficacy in both submerged and air-liquid interface (ALI) culture models, presenting a novel therapeutic strategy against hMPV.

Cited Product: PVV22901 | Anti-HMPV F/Fusion glycoprotein F0 Polyclonal Antibody

clonal Antibody

Application: This antibody was used in Western blot analysis (employing the Jess automated capillary system) to detect hMPV F protein expression, confirming that PHOH-001 treatment significantly downregulates F protein levels and providing key protein-level evidence for its antiviral mechanism.

The above are some of the scientific papers citing AntibodySystem products in February 2026. AntibodySystem can provide a full range of scientific research reagent products, including recombinant proteins, flow cytometry antibodies, anti-IgE antibodies, phosphorylated antibodies, and ELISA kits, which accurately serve fields such as drug target research, immunoassays, allergic mechanism exploration, and tumor treatment development.

New Citations in February 2026 2026-03-12 300